Dr. David C. Starks, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Michigan Medical School (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 217
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: University of Michigan Medical School
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
SD license 8518 -
Obstetrics & Gynecology Physician
OH license TRAINING
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Avera Mckennan Hospital & University Health Center Sioux Falls, SD
- Avera Marshall Regional Medical Ctr Marshall, MN
- Avera Queen of Peace Mitchell, SD
- Sioux Center Health Sioux Center, IA
- Pipestone County Medical Center Pipestone, MN
Medical groups
- Avera Mckennan (959 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 217
- Services billed
- 580
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 224 | 155 |
| Established patient office or other outpatient visit, 40-54 minutes | 107 | 27 |
| New patient office or other outpatient visit, 60-74 minutes | 29 | 29 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 21 | 21 |
| Biopsy and removal of lymph nodes of abdominal cavity using an endoscope | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Sioux Falls, SD | 53 |
| Megestrol Acetate Other prescribers in Sioux Falls, SD | 32 |
| Dexamethasone Other prescribers in Sioux Falls, SD | 26 |
| Zejula (niraparib tosylate) | 18 |
| Gabapentin Other prescribers in Sioux Falls, SD | 15 |
| Tramadol Hcl Other prescribers in Sioux Falls, SD | 15 |
| Ondansetron Odt (ondansetron) Other prescribers in Sioux Falls, SD | 14 |
| Venlafaxine Hcl Er (venlafaxine hcl) Other prescribers in Sioux Falls, SD | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 7 payments worth $7,004 in total to this clinician.
| Daiichi Sankyo Inc. | $2,590 |
|---|---|
| Merck Sharp & Dohme LLC | $2,240 |
| Genmab U.S., Inc. | $2,120 |
| Ethicon US, LLC | $19.90 |
| GlaxoSmithKline, LLC. | $19.28 |
| Pfizer Inc. | $15.20 |
| Consulting Fee | $6,950 |
|---|---|
| Food and Beverage | $54.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC Nov 3, 2025 | Consulting Fee | $2,240 |
| Genmab U.S., Inc. Jul 25, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $2,120 |
| Daiichi Sankyo Inc. Mar 3, 2025 | Consulting Fee | $1,554 |
| Daiichi Sankyo Inc. Mar 3, 2025 | Consulting Fee | $1,036 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 14 companies. The companies reported $1,885,950 in research payments for these studies, mostly to the institutions running them.
- A Phase III randomized study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib in patients with no germline BRCA mutation detected, platinum-resistant or refractory, high grade serou…
Novartis Pharmaceuticals Corporation - TAK-280-1501
Takeda Pharmaceuticals U.S.A., Inc. - Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06787612 - A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Beone Medicines Ltd. · Terminated · NCT05381909 - A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
Beone Medicines USA, Inc. · Recruiting · NCT06803680 - A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Karyopharm Therapeutics Inc. - Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Daiichi Sankyo Inc. · Recruiting · NCT06819007 - A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects with FR-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
AbbVie Inc. - Study name not reported
Iovance Biotherapeutics, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.